Pick Your Community: | Hopkins | Muhlenberg | Daviess | Christian | Fayette | Henderson | Lakes | McCracken | Warren | Webster
Davis Motor Sales banner ad

FDA Approves New Drug for Advanced Prostate Cancer

fda2WASHINGTON, D.C. (5/15/13) - The U.S. Food and Drug Administration today approved Xofigo (radium Ra 223 dichloride) to treat men with symptomatic late-stage (metastatic) castration-resistant prostate cancer that has spread to bones but not to other organs. It is intended for men whose cancer has spread after receiving medical or surgical therapy to lower testosterone.

Prostate cancer forms in a gland in the male reproductive system found below the bladder and in front of the rectum. The male sex hormone testosterone stimulates the prostate tumors to grow. According to the National Cancer Institute, an estimated 238,590 men will be diagnosed with prostate cancer and 29,720 will die from the disease in 2013.

Xofigo is being approved more than three months ahead of the product’s prescription drug user fee goal date of Aug. 14, 2013, the date the agency was scheduled to complete review of the drug application. The FDA reviewed Xofigo under the agency’s priority review program, which provides for an expedited review of drugs that appear to provide safe and effective therapy when no satisfactory alternative therapy exists, or offer significant improvement compared to marketed products.

“Xofigo binds with minerals in the bone to deliver radiation directly to bone tumors, limiting the damage to the surrounding normal tissues,” said Richard Pazdur, M.D., director of the Office of Hematology and Oncology Products in the FDA’s Center for Drug Evaluation and Research. “Xofigo is the second prostate cancer drug approved by the FDA in the past year that demonstrates an ability to extend the survival of men with metastatic prostate cancer.”

In August 2012, the FDA approved Xtandi to treat men with metastatic castration-resistant prostate cancer that has spread or recurred, even with medical or surgical therapy to minimize testosterone. Xtandi is approved for patients who have previously been treated the chemotherapy drug docetaxel.

Xofigo’s safety and effectiveness were evaluated in a single clinical trial of 809 men with symptomatic castration-resistant prostate cancer that spread to bones but not to other organs. Patients were randomly assigned to receive Xofigo or a placebo plus best standard of care.

The study was designed to measure overall survival. Results from a pre-planned interim analysis showed men receiving Xofigo lived a median of 14 months compared to a median of 11.2 months for men receiving placebo. An exploratory updated analysis conducted later in the trial confirmed Xofigo’s ability to extend overall survival.

The most common side effects reported during clinical trials in men receiving Xofigo were nausea, diarrhea, vomiting and swelling of the leg, ankle or foot. The most common abnormalities detected during blood testing included low levels of red blood cells (anemia), lymphocytes (lymphocytopenia), white blood cells (leukopenia), platelets (thrombocytopenia) and infection-fighting white blood cells (neutropenia).

Xofigo is marketed by Wayne, N.J.-based Bayer Pharmaceuticals. Xtandi is co-marketed by Astellas Pharma U.S., Inc. of Northbrook, Ill., and Medivation, Inc. of San Francisco, Calif.
 
SurfKY News
Information provided by the United States Food and Drug Administration

© Copyright 2014 SurfKY News Group, Inc. All rights reserved. This material may not be published, broadcast, or rewritten without permission. SurfKY News encourages you to share this story by using one of the social media links below.

In Other News...

Murray-Calloway County Hospital Concludes Mind, Body and Soul Challenge

MURRAY, Ky. (4/18/14) — Sgt. David Howe of the Murray Police Department was the grand prize winner of the Mind, Body… Read More

Kentucky State Parks Foundation Awards Grants for Trail Improvements

FRANKFORT, Ky. (4/20/14) — The Kentucky State Parks Foundation has awarded matching grants to two Kentucky State Parks… Read More

Most Read This Week (Site-Wide)

April 16, 2014 19795

UPDATE- Sheriff's Office Following Leads…

in Top Stories by Taylor Riley, SurfKY News Reporter
April 17, 2014 4482

KSP Nabs St. Charles Man Wanted by U.S.…

in Top Stories by Trooper Stu Recke
April 16, 2014 3438

Sheriff's Deputies Nab Central City…

in Top Stories by Sheriff Curtis McGehee
April 17, 2014 3261

Meet The Hopkins County Magistrate…

in News by Rita Dukes Smith, SurfKY News Director
April 16, 2014 1979

Rand Paul - 'We Need a New President'

in Top Stories by Paul McRee, SurfKY News Reporter

Most Read Stories from Hopkins County

April 17, 2014 4482

KSP Nabs St. Charles Man Wanted by U.S.…

in Top Stories by Trooper Stu Recke
April 18, 2014 1206

Talking Teen Trashed Telephone Pole,…

in Top Stories by MPD
April 18, 2014 974

Earlington Traffic Stop Results in Meth…

in Top Stories by Trooper Stu Recke
April 19, 2014 901

Fifth Third on Main Street Comes Down

in Top Stories by Rita Dukes Smith, SurfKY News Director
April 17, 2014 779

Center Street-Island Ford Connector in…

in Top Stories by Rebecca Hanchett

Most Read Stories from Owensboro

April 16, 2014 1269

New Home Health Care Opens in Owensboro

in News by Dennis Beard, SurfKY News
April 18, 2014 1242

Daviess County School Board Hears…

in News by Dennis Beard, SurfKY News
April 18, 2014 1205

One Arrested, Another Injured in Single…

in News by J.D. Marksberry
April 16, 2014 1034

DCPS to Celebrate National Volunteer Week

in News by Lora Wimsatt
April 17, 2014 337

Owensboro Public Works Declares 'War on…

in Top Stories by Abby Shelton

Most Read Stories from Muhlenberg County

April 16, 2014 3438

Sheriff's Deputies Nab Central City…

in Top Stories by Sheriff Curtis McGehee
April 16, 2014 1647

South Carrollton Woman Injured in Head-on…

in Top Stories by Trooper Stu Recke
April 17, 2014 1637

Bremen Man Charged for Possession of…

in Top Stories by Muhlenberg Sheriff Curtis McGehee
April 17, 2014 1456

Watson Family Tragedy Inspires Muhlenberg…

in Top Stories by Paul McRee, SurfKY News Reporter
April 16, 2014 1454

Three Injured in Kentucky 70 Collision

in Top Stories by Trooper Stu Recke

SurfKY News Group, Inc. Central Office & Printing Division
1125 Nebo Rd.  •  Madisonville, KY 42431  •  270.452.2249 (fax)
Main Number: 270.452.2727 (phone)  •  Printing Division Direct Line: 270.821.8600 (phone)

SurfKY Owensboro News Bureau
920 Frederica St. / Suite 210  •  Owensboro, KY 42301  •  270.683-8060 (phone)


Contact a member of our staff: www.surfky.com/contact
Copyright © 2014 SurfKY News Group, Inc.  •  Terms of Use  •  Site Map

social 06social 21social 22social 04social 03